## Humber Area Prescribing Committee

Agenda Number	Item	Discussion	Action	Lead	Due Date
2023.04.01	Apologies	Noted above			
2023.04.02	Declarations of interest	None			
2023.04.03	Minutes of previous meeting	Accepted as true record			
2023.04.04	Action Tracker	Prescription requests in primary care –action transferred from NLAPC to Humber APCTo produce joint document detailing supply details from secondary to primary care for all providers within Humber regionTo add links to relevant HUTH and NLAG guidance to 	Ongoing	JM	6/23
		Ratification of guidelines and SCFsAdd type 2 diabetes guidelines as recommendation for discussion at IMOC (action complete)NEW actionsTo feedback IMOC recommendation to cliniciansTo feedback to APC when meeting between all services occurredDecember update – going around internal governances in trusts (HUTH/NLAG/Y&SFT/HDH)March update – still awaiting outcome from relevant governances, JM to discuss with Matthew HeppelAction tracker HERPC – Hydroxychloroquine SCF	Ongoing Ongoing	JM	5/23
		JM to prepare hydroxychloroquine SCF Action tracker NLAPC – Triptorelin JM/AK to share HERPC guideline with Mr Rogers for transfer into a joint document December update still ongoing Discussion regard Mr Rogers and updating the costing	Document to be sent to Guideline group- Remove from tracker	JM/AK	3/23
		Outstanding actions from NLAPC	Riluzole- Approved in NL. JM to		

Funding for SCFs – mycophenolate, modafinil and riluzole	update website	JM/RS	6/23
(joint SCFs)	with change to	••••	0/20
December update: JM provided RS with patient numbers for	riluzole Others		
mycophenolate, modafinil and riluzole	ongoing		
Feb update- Modafinil live in NEL Riluzole live in NEL	5 5		
March update: SCFs uploaded onto Humber APC and linked			
into formulary. Awaiting NL – RS to update			
Outstanding actions from NLAPC			
Funding for SCF – Azathioprine/6MP (NEL/N)		AK	6/23
AK to provide RS information on number of patients in	Azathioprine		
NEL/NL	approved in NL		
Feb update Azathioprine live in NEL			
March update: SCF uploaded onto website, awaiting NL –			
RS to update			
Outstanding actions from NLAPC		RS	2/23
ADHD shared care (NL) – Awaiting confirmation of funding.	Ongoing/On		
Going to next mental health primary/secondary care interface	agenda as AOB		
meeting. RS to update when feedback received	5		
March update: Formulary updated ready for go live.			
Outstanding actions from NLAPC		RS	2/23
Atomoxetine liquid – SCF ADHD shared care NL awaiting	Ongoing		
funding (as per other action). NEL within current SCF.	0 0		
February update: planned for March go line for NL			
Outstanding actions from HERPC			
Renal repatriation:			
December update – JM to meet with renal		JM	12/22
Dec update – JM offered dates of meeting but no	Ongoing		
correspondence			
March update – Updating business case.			
Ratification of joint formulary			
To upload chapter 13 on netformulary and remove HERPC		JM/AK/LS	6/23
chapter	JM sent to RS		
March update – still ongoing			
Ratification of guidelines and SCFs		JM	4/23
Lithium for cluster headache – JM to look at potential patient	Action complete		
numbers in Northern Lincolnshire and send to RS			
Traffic light status	Action complete	AK/LS	4/23
To update formulary and red list			
Ratification of guidelines and SCFs		JM	4/23

		JM to complete updates requested on guidance and upload onto website, remove relevant HERPC guidance and note on HERPC website which guidance has moved to Humber APC guidance <b>RTDC updates</b> To update formulary with TAs which were approved	Action complete	JM/AK	4/23
2023.04.05	Outstanding actions from HERPC	Correspondence Received     Rheumatology to prepare pathway with rituximab without     MTX     August update – JM to contact Dr Ogumbambi for timeline     October update – JM to contact Dr Ogumbambi again     November update – Arranging meeting to discuss     guidance and timeframe     December update – Meeting booked     February update – Documents sent to Dr Ogumbambi –     March update – JM chased Dr Ogumbambi as received     NLAG documents	Ongoing	JM	9/22
		<ul> <li>Feedback From Commissioning Groups         KMc and JM to work with CCG to approve MS guideline             August update – JM to contact Gary Hepworth             September update – JM updated document and to send to             Gary Hepworth             October update – JM sent to Gary Hepworth             November update – Been circulated awaiting comments.             December update – JM to update and send to guideline             group for discussion             February update – to add to next guideline group for             discussion             March update – to add to next guideline group             Discussed at guideline group for next APC agenda         </li> </ul>	Ongoing- Add to next HAPC agenda	JM/KMc	12/22
		<ul> <li>Hydroxychloroquine SCF         JM to discuss ophthalmology checks with rheumatology New action: JM to add Harrogate pathway to agenda when published.     </li> <li>New Action: JM to meet with business manager in ophthalmology to discuss drafting HUTH pathway and work towards commissioning.</li> <li>September 2022 update – HUTH D&amp;T are escalating internally via their escalation process. To prepare SCG (action for HAPC)</li> <li>October 2022 – HUTH D&amp;TC haven't had reply from their escalation process (JM chasing)</li> </ul>	Ongoing- Not discussed at PE&CE- Discuss at HUTH D&T	JM	1/23

2023.04.06	Traffic Light Status	<ul> <li>November 2022 – HUTH D&amp;TC haven't had reply from their escalation process</li> <li>December 2022 – HUTH meeting later this month.</li> <li>February 2023 – To check PE&amp;CE minutes</li> <li>March 2023 – To discuss PE&amp;CE response at next D&amp;TC</li> <li>Prescribing guidelines – Dienogest pathway</li> <li>JM to confirm prescribing arrangements with specialist team</li> <li>October update: JM contacted Mrs Allen who is service lead, noted not stocked in HUTH pharmacy, thus stock arranged in pharmacy. No response from e-mail to consultant but specialist nurse responded.</li> <li>November update – JM to check formularies and EMIS dispensing system.</li> <li>December update – JM to chase consultant February update – JM met consultant and going to update pathway</li> <li>March update –JM to update pathway</li> <li>Nil this month</li> <li>Dexcom request- Discussed at guideline group Recommended for addition to formulary awaiting</li> </ul>	Ongoing- add to next guideline agenda Update formulary/red list	JM LS/AK	3/22 4/23
		funding, classification to be confirmed when pathway released			
2023.04.07	Feedback from Integrated Medicines Optimisation Committee	<ul> <li>Discussions on Finance, covid medicine supplies (working well) and subcommittee feedback</li> </ul>	Noted		
2023.04.08	Work plans	<ul> <li>a) Joint formulary alignment</li> <li>b) Shared care frameworks</li> <li>c) Guidelines</li> </ul>	Ongoing for information only		
2023.04.09	Ratification of guidelines and SCFs	<ul> <li>a) Distress in Dementia – CHCP document for use in care homes in Hull and East Riding of Yorkshire. Approved</li> <li>b) Anticoagulant in NVAF – approved to add to APC website. To remove the previous edoxaban document and add this to AF section.</li> </ul>	a) Approved b) Approved Circulate both for final approval with JG/SP and update website	JM	4/23
2023.04.10	Ratification of joint formulary	Nil this month			
2023.04.11	RTDC updates	Feb 23- to update formulary	Update formulary/red list	JM/LS/AK	4/23
2023.04.12	HAPC Newsletter	Draft newsletter discussed. JM to update with comments and March NICE and send to members for final approval.	Attached		
2023.04.13	Minutes from subcommittees	<ul><li>a) Joint formulary subcommittee (Nil)</li><li>b) Guideline subcommittee (Nil)</li></ul>	Attached for info only		

2023.04.14	Additional minutes for information	<ul> <li>a) HUTH D&amp;TC (Nil)</li> <li>b) HFT DTG (Nil)</li> <li>c) NLAG M&amp;T (Feb 23)</li> <li>d) NYY APC (Feb 23)</li> </ul>	Attached for info only	
2023.04.15	Correspondence received	<ul> <li>Cenobamate/out of area shared care</li> <li>Dementia medicines in NEL/NL</li> </ul>	RS to feedback	
2023.04.16	AOB	<ul> <li>Semaglutide TA875</li> <li>Transfer of prescribing from private providers</li> <li>ADHD SCF(NL only)- Updated</li> </ul>	Discussed Discussed Area representative GP to review SCF	
2023.04.17	Date of next meeting	3 <sup>rd</sup> May 13.00 – 15.00 Teams		